In June, the European Parliament and Council approve the creation of the EDCTP programme.
In September, 14 European Union Member Stated and Norway, with the support of the European Union, established EDCTP.
EDCTP launched 8 calls for proposals amounting to more than €20 M. It was the first time EDCTP member country co-funding was introduced for large capacity building and clinical trials calls.
Hosted by NWO, the EDCTP Europe Office opens in The Hague, Netherlands in February 2004. In July, the EDCTP Africa Office was launched in Cape Town, South Africa.
New calls to support the prevention of HIV in Africa were launched, including EDCTP’s first collaboration with Bill & Melinda Gates Foundation: €20M call to support capacity development to prepare for phase II clinical trials of HIV preventive vaccines.
EDCTP established its integrated approach: a grant scheme that combines clinical trials as a core component with networking and capacity strengthening activities.
The CHAPAS-1 team shared its preliminary pharmacokinetics data with the USA Food and Drug Authority (FDA) and the data contributed to the approval of a paediatric ARV formulation for use in HIV-infected children.
In December, the first of four Networks of Excellence was established: the Central African Network on Tuberculosis, HIV/AIDS and Malaria (CANTAM).
In September, the EDCTP-funded Pan African Clinical Trials Registry (PACTR) was officially recognised as a WHO Primary Registry. PACTR is the only WHO-endorsed primary registry in Africa.
The Kesho Bora study influenced revision of the 2010 WHO guidelines on prevention of mother-to-child transmission of HIV during breastfeeding.
Results from study by EDCTP Senior Fellow Prof. Mark Nicol (South Africa) contributes to WHO endorsement of the Xpert MTB/RIF assay
The 4ABC study supports WHO recommendation of DHAPQ as a treatment for uncomplicated Plasmodium falciparum malaria.
In March 2012, EDCTP received an EC Coordination and Support Action (CSA) grant. The EDCTP-Plus activities supported by this CSA grant are to consolidate the achievements of the first EDCTP programme and lay the foundation for the second programme.
EFPIA and EDCTP signed a Memorandum of Understanding on a clinical R&D fellowship through placements of sub-Saharan African researchers in European-based pharmaceutical companies.
The second EDCTP programme (EDCTP2) is EDCTP2 launched.
EDCTP2 launched in Cape Town, South Africa on 2 December.
Historic step: 11 African countries join EDCTP as members.
REMSTART trial showed that a new approach to HIV management incorporating community support and early screening for cryptococcal meningitis reduced deaths by 28%.
The EMA publishes positive scientific opinion on Pyramax® based on data from a clinical trial conducted by the WANECAM study.
EDCTP receives Science Diplomacy Award at South African Science Forum
The first EDCTP programme closed in December.
In October, EDCTP appointed two High Representatives: Dr Leonardo Santos Simão (High Representative for Africa) and Professor Marcel Tanner (High Representative for Europe).
At the Eighth EDCTP Forum, the Dr Pascoal Mocumbi Prize is awarded for the first time.
The PredART trial showed that a readily available drug, prednisone, significantly reduced the risk of TB-IRIS in patients being treated for TB who were starting antiretroviral therapy.
EDCTP Alumni Network launched at a workshop in Johannesburg, South Africa on 3 and 4 October.
Three African countries joined the EDCTP Association: Nigeria and Nigeria.
Launch of two EDCTP-funded epidemic research preparedness consortia: ALERRT and PANDORA-ID-NET.
The TRUST project delivers the Global Code of Conduct for Research in Resource-Poor Settings.
EDCTP launches its Emergency Funding initiative for the first time to support research activities in response to the Ebola outbreak in the Democratic Republic of Congo.
Key achievements timeline